1. Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826). (October 2022) Authors: Hamilton, E.; Meisel, J.; Alemany, C.; Virginia, B.; Lin, N.; Wesolowski, R.; Mathauda-Sahota, G.; Makower, D.; Lawrence, J.; Faltaos, D.; Mitri, Z.; Sabanathan, D.; Clark, D.; Pluard, T.; Hui, R.; McCarthy, N.; Patel, M. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Planning for groundwater sustainability accounting for uncertainty and costs: An application to California's Central Valley. (15th June 2020) Authors: Escriva-Bou, A.; Hui, R.; Maples, S.; Medellín-Azuara, J.; Harter, T.; Lund, J.R. Journal: Journal of environmental management Issue: Volume 264(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Quantitative analysis of surface enhanced Raman spectroscopy of Rhodamine 6G using a composite graphene and plasmonic Au nanoparticle substrate. (January 2017) Authors: Goul, Ryan; Das, Susobhan; Liu, Qingfeng; Xin, Melisa; Lu, Rongtao; Hui, R.; Wu, Judy Z. Journal: Carbon Issue: Volume 111(2017) Page Start: 386 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 33LBA Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Enrolled in KEYNOTE-001. Issue 3 (September 2015) Authors: Soria, J.C.; Flatten, O.; Horn, L.; Felip, E.; Gandhi, L.; Hui, R.; Hellmann, M.; Leighl, N.; Zhang, J.; Kondic, A.; Rangwala, R.; Lubiniecki, G.M.; Garon, E.B. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S726 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study. (April 2023) Authors: Kümmel, S.; Schmid, P.; Harbeck, N.; Takahashi, M.; Untch, M.; Boileau, J.-F.; Cortes, J.; McArthur, H.; Dent, R.; O'Shaughnessy, J.; Pusztai, L.; Foukakis, T.; Park, Y.H.; Hui, R.; Cardoso, F.; Denkert, C.; Zhu, Y.; Pan, W.; Karantza, V.; Fasching, P. Journal: Breast Issue: Volume 68(2023)Supplement Page Start: S63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗